1. Home
  2. EFC vs ZYME Comparison

EFC vs ZYME Comparison

Compare EFC & ZYME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EFC
  • ZYME
  • Stock Information
  • Founded
  • EFC 2007
  • ZYME 2003
  • Country
  • EFC United States
  • ZYME United States
  • Employees
  • EFC N/A
  • ZYME N/A
  • Industry
  • EFC Real Estate
  • ZYME Biotechnology: Pharmaceutical Preparations
  • Sector
  • EFC Finance
  • ZYME Health Care
  • Exchange
  • EFC Nasdaq
  • ZYME Nasdaq
  • Market Cap
  • EFC 1.4B
  • ZYME 1.2B
  • IPO Year
  • EFC 2010
  • ZYME 2017
  • Fundamental
  • Price
  • EFC $13.60
  • ZYME $18.03
  • Analyst Decision
  • EFC Strong Buy
  • ZYME Strong Buy
  • Analyst Count
  • EFC 7
  • ZYME 8
  • Target Price
  • EFC $14.46
  • ZYME $24.00
  • AVG Volume (30 Days)
  • EFC 1.2M
  • ZYME 665.2K
  • Earning Date
  • EFC 11-05-2025
  • ZYME 11-06-2025
  • Dividend Yield
  • EFC 11.50%
  • ZYME N/A
  • EPS Growth
  • EFC N/A
  • ZYME N/A
  • EPS
  • EFC 1.24
  • ZYME N/A
  • Revenue
  • EFC $312,485,000.00
  • ZYME $122,867,000.00
  • Revenue This Year
  • EFC N/A
  • ZYME $107.76
  • Revenue Next Year
  • EFC $7.92
  • ZYME $2.35
  • P/E Ratio
  • EFC $10.96
  • ZYME N/A
  • Revenue Growth
  • EFC 10.76
  • ZYME 95.94
  • 52 Week Low
  • EFC $11.12
  • ZYME $9.03
  • 52 Week High
  • EFC $14.40
  • ZYME $19.50
  • Technical
  • Relative Strength Index (RSI)
  • EFC 56.75
  • ZYME 64.55
  • Support Level
  • EFC $13.50
  • ZYME $18.21
  • Resistance Level
  • EFC $13.78
  • ZYME $19.10
  • Average True Range (ATR)
  • EFC 0.20
  • ZYME 0.69
  • MACD
  • EFC 0.04
  • ZYME 0.02
  • Stochastic Oscillator
  • EFC 76.44
  • ZYME 55.45

About EFC Ellington Financial Inc.

Ellington Financial Inc is a specialty finance company. Its primary investment objective is to generate attractive, risk-adjusted total returns for its shareholders by making investments. The company has two reportable segments; The Investment Portfolio Segment is focused on investing in a diverse array of financial assets, including residential and commercial mortgage loans, residential mortgage-backed securities, non-mortgage- and mortgage-related derivatives, debt and equity investments in loan origination companies, and other strategic investments, and The Longbridge Segment is focused on the origination and servicing of reverse mortgage loans. it acquires reverse mortgage loans both through its origination activities and through secondary market purchases.

About ZYME Zymeworks Inc.

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.

Share on Social Networks: